Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
PepGen Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Statements of Operations Three Months EndedJune 30, 2023 2022 Operating expenses: Research and development $ 16,926 $ 14,240 General and administrative 4,218 3,401 Total operating expenses $ 21,144 $ 17,641 Operating loss $ $ Other income Interest income 1,684 250 Other income , net 76 Total other income , net 1,622 326 Net loss before income tax $ $ Income tax expense - - Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,790,430 14,090,455 Condensed Consolidated Balance Sheets June 30,2023" |
|
| 05/18/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Statements of Operations Three Months EndedMarch 31, 2023 2022 Operating expenses: Research and development $ 14,360 $ 10,707 General and administrative 3,671 3,186 Total operating expenses $ 18,031 $ 13,893 Operating loss $ $ Other income Interest income $ 1,792 $ 9 Other income , net 58 Total other income , net $ 1,712 $ 67 Net loss before income tax $ $ Income tax expense — Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 23,761,915 963,588 Condensed Consolidated Balance Sheets March 31,2023" |
|
| 03/27/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Statements of Operations Twelve Months Ended December 31, Three Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 54,077 $ 18,999 $ 13,166 $ 4,541 General and administrative 14,224 8,110 4,047 2,670 Total operating expenses $ 68,301 $ 27,109 $ 17,213 $ 7,211 Operating loss $ $ $ $ Other income Interest income 2,793 — 1,591 — Other income , net 110 67 Total other income , net 2,903 1,563 67 Net loss before income tax $ $ $ $ Income tax expense — 714 — Net loss $ $ $ $ Condensed Consolidated Balance Sheets December 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 181,752 $ 132,895 Other receivables 58 4,744 Prepaid expenses and other current assets 4,273 2,347 Total current assets $ 186,083 $ 139,..." |
|
| 03/22/2023 |
8-K
| Quarterly results |
| 12/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/28/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SCIENTIFIC ADVISORY BOARD MEMBER AGREEMENT This Scientific Advisory Board Member Agreement, effective 1st August, 2022 , is between PepGen Inc., a Delaware corporation, and Caroline Godfrey, an individual residing at the address set forth on the signature page hereto . In light of Advisor's expertise in areas consistent with Company's research and development, business and product strategy, Company and Advisor agree as follows: 1. Services. Advisor agrees to contribute to Company's success by attending informal and formal meetings of the Company’s Scientific Advisory Board and to provide such consulting, advisory and related services to and for the Company from time to time, at Company's request . Services may be rendered in person, or by telephone, electronic mail or other means. While th..." |
|
| 06/16/2022 |
8-K
| Quarterly results|
Docs:
|
"Condensed Consolidated Statements of Operations Three Months Ended March 31, 2022 2021 Operating expenses: Research and development $ 10,707 $ 5,530 General and administrative 3,186 1,098 Total operating expenses $ 13,893 $ 6,628 Operating loss $ $ Other income Interest income 9 — Other income , net 58 Total other income , net 67 Net loss before income tax $ $ Income tax expense — Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 963,588 894,060 Condensed Consolidated Balance Sheets March 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 118,854 $ 132,895 Other receivables 4,574 4,744 Prepaid expenses and other current assets 2,240 2,347 Total current assets $ 125,668 $ 139,986 Property and equip..." |
|
|
|